Press Releases

Press Releases

Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts


Incheon, Korea, December 3, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESG action among suppliers.


Second of its kind, the event was held virtually to invite more domestic and global suppliers, with over 82 companies, including Merck, Cytiva, Thermo Fisher, and Sartorius, taking part.


“As the healthcare industry is one of the largest carbon emitters, it is our responsibility to be at the forefront of efforts to promote sustainable value chains,” said John Rim, CEO and President of Samsung Biologics. “We will continue to support our suppliers to strengthen their ESG management and work together to build a greener and circular future.” 


Samsung Biologics shared its knowhow in ESG management and progress made so far. Aiming to achieve net zero by 2050, the global CDMO has been bolstering sustainable operations by utilizing low-carbon technologies, such as ultra-low NOx boilers and energy monitoring systems, and accelerating the transition to renewable energy by installing onsite solar panels. In recognition of its efforts, the company was awarded the Terra Carta Seal from the Sustainable Markets Initiative (SMI) and achieved a platinum rating from EcoVadis, the highest rank given. Samsung Biologics has been engaging suppliers, alongside global pharmaceutical companies, to decarbonize and build more resilient value chains as champion of the Supply Chains Working Group within the SMI Health Systems Task Force.


Samsung Biologics also encouraged suppliers to contribute to building more sustainable global value chains, by staying ahead of various global reporting standards, including the European Union Corporate Sustainability Due Diligence Directive, European Sustainability Reporting Standards, and International Financial Reporting Standards.


External ESG specialists were also invited to provide insights on ESG-related requirements and share sustainability reporting and disclosure tools applicable to small and mid-sized companies.


Incheon, Korea, December 3, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESG action among suppliers.


Second of its kind, the event was held virtually to invite more domestic and global suppliers, with over 82 companies, including Merck, Cytiva, Thermo Fisher, and Sartorius, taking part.


“As the healthcare industry is one of the largest carbon emitters, it is our responsibility to be at the forefront of efforts to promote sustainable value chains,” said John Rim, CEO and President of Samsung Biologics. “We will continue to support our suppliers to strengthen their ESG management and work together to build a greener and circular future.” 


Samsung Biologics shared its knowhow in ESG management and progress made so far. Aiming to achieve net zero by 2050, the global CDMO has been bolstering sustainable operations by utilizing low-carbon technologies, such as ultra-low NOx boilers and energy monitoring systems, and accelerating the transition to renewable energy by installing onsite solar panels. In recognition of its efforts, the company was awarded the Terra Carta Seal from the Sustainable Markets Initiative (SMI) and achieved a platinum rating from EcoVadis, the highest rank given. Samsung Biologics has been engaging suppliers, alongside global pharmaceutical companies, to decarbonize and build more resilient value chains as champion of the Supply Chains Working Group within the SMI Health Systems Task Force.


Samsung Biologics also encouraged suppliers to contribute to building more sustainable global value chains, by staying ahead of various global reporting standards, including the European Union Corporate Sustainability Due Diligence Directive, European Sustainability Reporting Standards, and International Financial Reporting Standards.


External ESG specialists were also invited to provide insights on ESG-related requirements and share sustainability reporting and disclosure tools applicable to small and mid-sized companies.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION